NEW YORK – Transplant Genomics announced Wednesday it has partnered with Viracor Eurofins, as well as Quest and other mobile sample collection groups, to facilitate remote sample collection for kidney transplant recipients.
The testing services include Transplant's TruGraf blood test to rule out silent kidney transplant rejection and Viracor Eurofins' TRAC liquid biopsy test to analyze donor-derived cfDNA levels in blood to rule out transplant rejection.
Through the partnership, patients won't be required to visit transplant centers for their health to be monitored, since the outbreak of SARS-CoV-2 has resulted in patients reducing office visits, Viracor Eurofins said.
Patients can also have samples tested for SARS-CoV-2, after Viracor Eurofins made its Coronavirus SARS-CoV-2 RT-PCR test available last week. The company also announced a partnership with the National Kidney Registry to provide thousands of testing kits for the registry's member centers.